Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SSTY news Announces Deal to Acquire NASDAQ Bulletin Board Company
PR Newswire - February 10, 2006 11:25
Feb 10, 2006 /PRNewswire-FirstCall via COMTEX/ -- Sure Trace Security Corporation (OTC: SSTY) today announced that it has signed an agreement to acquire the controlling interest in a company presently trading on the NASDAQ OTC Bulletin Board.
The agreement calls for the acquired company to be renamed True Product ID-US ("TPiD-US"). TPiD-US shall be granted, at closing, a Master License from SSTY to conduct all marketing and administrative rights, duties, responsibilities and obligations presently held by SSTY and its subsidiaries (except for those granted/reserved to SSTY or other parties prior to closing), including the rights, duties, responsibilities and obligations for the company's activities in China and the rest of the world.
SSTY will receive all but between 5 to 10% the shares of TPiD-US in exchange for cash consideration. TPiD-US, as a consequence of the transaction, will become a subsidiary of SSTY. SSTY's board intends to then approve the spin-off of TPiD-US through the dividend of 100% of the SSTY shares of TPiD-US to all shareholders of SSTY. The dividend will be payable on a record date to be determined by the SSTY board. Fractional shares of TPiD- US common stock will not be issued and any SSTY shareholder entitled to receive a fractional share will instead receive a cash payment. The shares issued to SSTY shareholders shall be restricted. SSTY shareholders will retain their present shares in SSTY.
The dividend has been structured to qualify as a tax-free stock dividend to SSTY stockholders for U.S. federal income tax purposes. Cash received in lieu of fractional shares, however, will be taxable.
Shortly after the dividend record date, SSTY will mail an information statement to its stockholders of record as of the close of business on the record date. The information statement will include information regarding the dividend and the business and management of TPiD-US following the distribution. In addition, SSTY and TPiD-US intend to file important information related to the spin-off, including this release, with the Securities and Exchange Commission on Form 8-K.
Closing is anticipated to be March 16, 2006 but may be moved in advance or back upon mutual agreement of the parties.
The terms of the Master License to be granted to TPiD-US will call for TPiD-US to pay a monthly minimum payment to SSTY in addition to a five percent (5%) royalty of the gross revenues received by TPiD-US under the worldwide license.
"We hope to follow this template (that is, a monthly minimum will be paid to SSTY and shares in the public company will be delivered to SSTY's then- present shareholder base) with at least one other subsidiary of SSTY, Globe Staff," said James Mackay, SSTY Chairman, although he cautioned that no specific plans exist for Globe Staff at this time.
Michael Cimino, SSTY President, said: "This arrangement will allow SSTY shareholders to hold, in addition to their shares in SSTY, shares in the acquired company, for which there will be publicly disclosed bids and asks, as well as the other features of the OTCBB. The arrangement will also provide a potential source of regular income to SSTY. We foresee no further need to raise additional funds for SSTY, which would eliminate further dilution of SSTY stock. In addition, it transfers the funding burden from SSTY to TPiD-US and Globe Staff respectively, along with the responsibility for their operations." He continued: "This new company will have new management, with specific experience in building global companies and their worldwide operation systems. Our plans are to have that management in place prior to the closing date on the acquisition."
About Sure Trace Security Corporation
Sure Trace produces integrators for anti-counterfeiting and security surveillance applications and is a provider of integrated tracking devices. The Company intends to deliver turnkey solutions for governments, armed forces, and industry, through its own proprietary technology and through aggregating the technology, products, and services of third parties via licensing agreements and or joint ventures. For more information go to: http://www.suretrace.com.
SAFE HARBOR STATEMENT: This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that our products may not achieve customer acceptance or perform as intended, that we may be unable to obtain necessary financing to continue operations and development, and other risks. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof and Sure Trace undertakes no obligation to update such statements. In August 2005, the common stock of Sure Trace was suspended from trading by the Securities and Exchange Commission, but the suspension ended in accordance with the securities laws after ten days. Management of Sure Trace is currently working with the broker-dealer community and regulators to permit quotations to be entered as soon as possible. More information will be provided to the public when circumstances warrant.
SOURCE Sure Trace Security Corporation
Michael Cimino, President, Sure Trace Security Corporation, +1-215-972-6999, or
michaelc@suretrace.com
http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
--------------------------------------------------------------------------------
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
JPHC has a release out 2, additional info on corporate Plans
PAIM -Your Wish is My CommandCompany Profile for Pearl Asian Mining Industries, Inc.
Business Wire - February 10, 2006 10:40
Feb 10, 2006 (BUSINESS WIRE) -- Pearl Asian Mining Industries, Inc. (OTC:PAIM) and its wholly owned subsidiary, Philippines Gold Mining Corporation (OTC:PGMC), together are multi-national mining companies engaged in exploration, development, mining, processing, property acquisition, marketing of products, to benefit both the small-scale and big-scale mining operations, and revitalizing the old and abandoned mining properties into a profit generating business in collaboration with the Philippine Government.
Pearl Asian Mining's (OTC:PAIM) and Philippines Gold Mining Corporation's (OTC:PGMC) vision and mission for the development of the mining industry is to partner with the Philippine Government and its host communities in order to acquire abandoned mines with known and proven reserves left for centuries. Similarly, it is the intention of the company to develop an environmentally friendly and sustainable operation adopting the best mining practice and projecting low Capital Cost projects, yet income generating business company. It is the goal of the company to strongly focus on the optimization and extraction of valuable minerals using non-toxic, environmentally safety Gold Processing & Chemical Methodology, while at the same time aiming to provide to the community upliftment by strengthening the local governance and enhancement of the living standards of its employees and host communities as a whole, thus offering sustainable economic growth.
The company has engaged the services of seasoned mining experts, highly experienced field engineers and team support professionals, who have good experience on the implementation of this gold / silver mining operations, domestically and internationally.
Company: Pearl Asian Mining Industries, Inc.
Headquarters Address: 3101-B East Tower, PSE Center
Philippines Stock Exchange,
Ortigas, Exchange Road
Pasig City, Metro Manila, Rizal 1605
Philippines
Main Telephone: +63-2-490-0140
Website: www.PearlAsianMining.com
Ticker: (OTC:PAIM);(OTC:PGMC)
Type of Organization: Public
Industry: Natural Resources: Mining/Minerals
Key Executives: President: Randolf Villanueva
Vice-Pres/CRO: Fr. Ariel Caleon
Chief Mining Officer: Engr. Socrates Serrano
Chairman / Founder
Contact: E. Pearl Asian
Phone: 866-732-7888
Email: IR@PearlAsianMining.com
Corporate Secretary
Contact: Sandy Winick
Phone: 416-918-2209
Email: swinick22@hotmail.com
Sr. Advisor
Contact: Engr. Pete Caleon
Phone: +63-2-490-0140
Email: acaleon@PearlAsianMining.com
SOURCE: Pearl Asian Mining Industries, Inc.
Copyright Business Wire 2006
--------------------------------------------------------------------------------
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
Your welcome PAIM just got a company profile
USXP NEWS Universal Express Retains Francorp Franchising Firm
Business Wire - February 10, 2006 10:36
NEW YORK, Feb 10, 2006 (BUSINESS WIRE) -- Universal Express Inc. (OTCBB: USXP), through its subsidiary Luggage Express announced today that it has engaged the services of the nations premier franchising organization, Francorp, Inc. (www.francorp.com) to guide and assist Universal Express in the franchising process for its L.E.A.P. (Luggage Express Associate Program) division.
"As our shareholders heard during our most recent web cast, we expect to have the franchise rights for L.E.A.P. legally in place with the Federal government and the 23 required states within 90 days," said Richard A. Altomare, CEO and Chairman of Universal Express, Inc.
"Due to our strong belief in the Luggage Express concept, we are excited to begin this journey with them. Francorp has worked with hundreds of companies wishing to franchise over the past 30 years, and we believe that Luggage Express will be one of the great successes in our history," stated L. Patrick Callaway, President of Francorp.
"Luggage Express and L.E.A.P have been pursued by numerous individuals since its announcement. We are anticipating tremendous success with this venture and anticipate sharing it with our future partners. L.E.A.P. purchasers will not only be receiving a Luggage Express sales area, but they will begin a partnership with our association (UECA) courier companies and our UniversalPost trade association postal locations to enhance and strengthen their business model," concluded Mr. Altomare.
About Universal Express
Universal Express, Inc. is a 22 year old logistics and transportation conglomerate with multiple developing subsidiaries and services. For additional information please visit www.usxp.com and www.myluggageexpress.com.
Safe Harbor Statement under the Private securities Litigation Reform Act of 1995: The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements including, but not limited to, certain delays beyond the Company's control with respect to market acceptance of new technologies, products and services, delays in testing and evaluation of products and services, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.
SOURCE: Universal Express Inc.
Universal Express, Inc.
Mark Falk, 631-588-1644
publicrelations@usxp.com
Copyright Business Wire 2006
--------------------------------------------------------------------------------
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
IMNR - News - Data Indicate That Whole-Inactivated HIV-1 Immunogen Induces HIV-Specific Immune Responses in HIV-Infected, HAART-Naive Patients; Final Data from IMNR.OB's Italian Study Presented in Poster at CROI Annual Meeting
Business Wire - February 10, 2006 07:00
CARLSBAD, Calif., Feb 10, 2006 (BUSINESS WIRE) -- The Immune Response Corporation (OTCBB:IMNR) announced today that the final results from a Phase II clinical study indicate that the Company's whole-inactivated HIV-1 immunogen induces HIV-specific immune responses in HIV-infected, antiretroviral drug-naive patients. Specifically, this original formulation product showed potential to stimulate key immunologic parameters and to stabilize the loss of CD4+ cells, which could help prolong the time before these patients need to initiate antiretroviral therapy. The poster was presented at this week's 13th Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.
Mourning All
CHMS _ NEWS China Mobility Solutions, Inc. Reports Q4 2005 Sales up 62% Year on Year
PR Newswire - February 10, 2006 08:30
VANCOUVER, British Columbia, Feb 10, 2006 /PRNewswire-FirstCall via COMTEX/ -- China Mobility Solutions, Inc., a Florida corporation (OTC Bulletin Board: CHMS) ("China Mobility") is pleased to announce its fourth quarter sales.
The fourth quarter was the highest-sale quarter of the year, and December reported the highest monthly sales of 2005, close to U$0.9 Million. Total sales from Chinese operations grew 62% year-over-year in the fourth quarter of 2005 to a new record of $1.92 million. Our client base has increased 33% sequentially and reached 30,000. At the end of the quarter, the Company had about $6 million in cash and cash equivalents. Cash flow from operating activities in China continues to grow.
Commenting on the results, President Angela Du said, "The fourth quarter went extremely well. With the growth in our mobile marketing solution and the addition of our newly introduced products, the fourth quarter showed continued growth in revenues."
Recent Development
In November China Mobility signed a contract with Lenovo, the world's third largest PC manufacturer, for distribution of its mobile email system throughout China. In December the Company added a new director, Bryan D. Ellis, to the Board of Directors. The Company also completed the transaction of the Quicknet agreement with the final payment made at the end of December. China Mobility now controls 100% interest in Quicknet.
About China Mobility Solutions Inc.
China Mobility Solutions, Inc. (OTC Bulletin Board: CHMS), a pioneer in developing Short Message Services (SMS) as a primary advertising medium in China, provides mobile marketing, branding and enterprise solutions to its rapidly expanding client base of Small and Medium Enterprises (SME). China Mobility also provides other mobile solutions such as mobile email systems and mobile solutions for field sales to SME. Through proprietary profit sharing agreements, China Mobility's advertising audience includes SMS subscribers from China Mobile, China Unicom and China Telecom.
Forward-looking statements
This report contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. All statements other than statements of historical facts included in this report, including, without limitation, the statements regarding our mission to become the number one provider of mobile solutions to businesses in China are forward-looking statements. Forward-looking statements involve risks and uncertainties including, but not limited to, economic and political factors; developments of the Chinese and North American markets and changes in regulatory matters; our business strategies and future plans of operations; the market acceptance and amount of sales of our products and services; our historical losses; the competitive environment within the industries in which we compete; and our ability to raise additional capital, currently needed for expansion.
The Company cautions that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements due to several important factors.
Contact:
Angela Du, President
China Mobility Solutions Inc.
900-789 W. Pender Street
Vancouver, B.C.
Contact Number: 604-632-9638
Email: investors@chinamobilitysolutions.com
Website: www.chinamobilitysolutions.com
SOURCE China Mobility Solutions Inc.
Angela Du, President of China Mobility Solutions Inc., +1-604-632-9638,
investors@chinamobilitysolutions.com
http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
--------------------------------------------------------------------------------
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
BGAT reports profits up over 100%
news came on different wire can't copy to this computer
TXHG- News - TX Holdings Acquires Exclusive Option on 14.5M Barrel Reserve
Business Wire - February 10, 2006 08:37
MIAMI, Feb 10, 2006 (BUSINESS WIRE) -- TX Holdings, Inc. (Pink Sheets:TXHG); the "Company") is pleased to announce it has purchased an exclusive option to buy the "Williams" leases situated in Callahan County, Texas. This option encompasses 843 acres of proven producing oil and gas leases, with estimated reserves of 14,500,000 barrels of oil with projected recovery rates of 40-50%. When these wells were first drilled, production was in excess of 10,000 barrels per month.
Of the entire lease approximately 343 acres have been developed to production, the remainder (500 acres) has yet to be fully developed and holds exciting potential for increased production and development. Production comes from the Fry, Tannehill and Bluff Creek formations, with the leases currently supporting 28 shallow wells (depths of less than 500 feet) and 5 deep wells (depth of 1800-4000 feet)
TX Holdings has contracted with top geological and reserve engineering specialists in order to validate the reserves as documented by a study conducted by the U.S. Department of Commerce and also in a supplemental reserve report conducted by Masada Oil and Gas. This due diligence is to ensure that all the title work, reserve estimates and geological data are as represented by the seller.
TX Holdings is very excited about the potential of this acquisition and anticipates closing on this property within 30 days subject to the timeliness of the engineering studies as well as the accuracy of the stated reserve reports. Upon finalizing the acquisition the company feels a comprehensive rework, re-completion and re-pressurization program on the lease will yield a very profitable long term acquisition for the company.
The information provided in this Press Release does not constitute an offer or a solicitation of an offer for the purchase or sale of any shares or other securities of TX Holdings, Inc. There are substantial risks associated with investing in development stage energy exploration companies. No securities commission or similar authority has in any way approved any of the information contained in this press release.
This Press Release contains 'forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this Press Release which are not historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date indicated, and TX Holdings, Inc. assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.
SOURCE: TX Holdings, Inc.
TX Holdings
Mark Neuhaus, 305-420-6781
www.txholdings.net
Copyright Business Wire 2006
--------------------------------------------------------------------------------
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
RVMN NEWS __Raven Moon Announces Revision to Warrant Exercise Window and Reverse Stock Split
Business Wire - February 10, 2006 08:31
ORLANDO, Fla., Feb 10, 2006 (BUSINESS WIRE) -- Raven Moon Entertainment, Inc. (OTCBB:RVMN) today announced that the exercise window for its previously announced 75-for-1 warrant dividend has been changed to February 18 through April 18, 2006. The record date for the warrant dividend remains February 10, 2006. The company also announced a 1:75 reverse stock split with an effective date of February 17, 2006.
"The recent 5-for-1 forward split and continued low share price has caused our Board to approve a reverse split so that an ask price and a bid price can be tracked by our shareholders on Yahoo, Alphatrade, or Scottrade," said Joey DiFrancesco, Chairman and CEO of Raven Moon Entertainment. "The reverse split will have the effect of reducing the number of shares and correspondingly increasing the price per share. The net effect of the change in the exercise window for the warrants and the reverse split will be to leave those shareholders who exercise warrants with the same number of shares, although they will have supported the company's long-term efforts by having exercised their warrants."
Mr. DiFrancesco continued, "Our overarching goal is to provide value for our shareholders by building a profitable company. Our business model requires a great deal of investment to generate interest in our Gina D brand and we have made progress, although we are not yet generating recurring revenue. We are working to put the company in the position of generating sustainable profits that will eventually be rewarded by the market. In the meantime, we are grateful to our shareholders for helping us continue to grow the company."
Time line
February 10, 2006 - record date for 75-for-1 warrants. Shareholders receive one warrant for every one share held at this date. Each warrant allows shareholders to purchase 75 shares at a 25% discount to the bid price on the day the shareholder writes a check to purchase the shares.
February 17, 2006 - effective date for 1:75 reverse split. Shareholders will have the number of shares they hold reduced by a 1:75 ratio.
February 18 through April 18, 2006 - exercise window for 75-for-1 warrants.
Terms of 75-for-1 Warrants
The terms of the warrant dividend are: shareholders of record as of February 10, 2006 shall receive 1 warrant for each share of common stock owned as of that date. The warrant allows the shareholder to exercise 75 shares of common restricted stock for each warrant they own and exercise during a two-month window beginning February 15, 2006 to April 15, 2006 at a 25% discount of the closing bid price on the day their check is dated. Common shares purchased as a result of exercising warrants will be restricted for one year. The company does not intend to charge a fee to process the warrants exercised.
Instructions for Exercising the 75-for-1 Warrants
Between February 18, 2006 and April 18, 2006, if your account is with a broker and you have not received a physical warrant, have the broker send a letter to Raven Moon Entertainment, 120 International Parkway, Suite 220, Heathrow, FL 32746 no later than April 18, 2006 verifying the number of shares you owned in your account as of February 10, 2006. Indicate the number of warrants you would like to exercise at a 25% discount of the closing bid on the day you write your check and make it payable to Raven Moon Entertainment, Inc.
If you have received a physical warrant from the company, fill it out and indicate the number of warrants you wish to exercise at a 25% discount of the closing bid on the day you write your check and make it payable to Raven Moon Entertainment, Inc. Upon receipt, the company will authorize the transfer agent to issue the shares to you.
About Raven Moon Entertainment, Inc.
Raven Moon Entertainment, Inc. is involved with the production of family entertainment programs for television, VHS tapes, DVDs, music CDs and related toys. Raven Moon has produced 24 episodes of Gina D's Kids Club(R), which started airing in September 2004 and is currently carried on 227 television stations nationwide. In November 2005, the company signed an exclusive agreement with public television station WPBT-Miami to offer the programs through American Public Television (APT) to public stations across the country for a June 2006 launch.
For more information on Raven Moon Entertainment and Gina D's Kids Club(R), visit http://www.ravenmoon.net or http://www.ginadskidsclub.com.
Safe Harbor Act Notice: This release may contain forward-looking statements that involve risks and uncertainties, including without limitation, acceptance of the company's products, increased levels of competition, product and technological changes, the company's dependence upon financing and third-party suppliers, and other risks detailed from time to time in the company's federal filings, annual report, offering memorandum or prospectus. Specifications are subject to change without notice.
SOURCE: Raven Moon Entertainment, Inc.
For Raven Moon Entertainment, Inc., Orlando
Fahlgren Mortine Investor Relations
Carol Merry, 614-825-1750
carol.merry@fahlgren.com
Copyright Business Wire 2006
--------------------------------------------------------------------------------
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
JYSR- News - Joystar, Inc. Announces Chinese Investor Files 13D-1 After Increasing Stake in Company
By Market Wire
Last Update: 2/10/2006 8:00:10 AM Data provided by
ALISO VIEJO, CA, Feb 10, 2006 (MARKET WIRE via COMTEX) -- Joystar, Inc. (JYSR), one of the nation's largest and fastest-growing travel agency networks and leading seller of cruises and vacations, announced today that Jeffrey Wu, a.k.a. Myint J. Kyaw has filed with The Securities and Exchange Commission, confirming his ownership of over 20% of the outstanding shares of the Company.
On December 30, 2005, Mr. Wu filed with the Securities and Exchange Commission, representing he had accumulated 3,547,227 shares of the Company's common stock. On January 30, 2006, Mr. Wu purchased 4,000,000 shares of restricted common stock directly from the Company.
The most recent filing stated he has been accumulating Joystar common stock and as a result of his accumulation now owns 8,583,957 shares. In the filing, he also stated he "may seek to change or influence the control of the Issuer, or in connection with or as a participation in any transaction having that purpose or effect."
William M. Alverson, President and CEO of Joystar, Inc., stated, "Mr. Wu continues to prove his commitment to Joystar by supporting our rapid organic growth strategy. The most recent infusion of capital will enable Joystar to begin to market leisure travel to the North American Asian community. Additionally, his other business interests provide services to the approximate 12 million Asian American population and will help give Joystar a keen insight and perspective on the unique nuances of selling complex travel to this very important market."
About Joystar
Joystar is the one of the nation's largest and fastest-growing leisure travel agency networks and a leading seller of cruises and vacations. The Company sells complex travel products including cruises, vacation packages and group travel through its growing national sales force of virtual travel agents and online affiliates. Joystar offers comprehensive business opportunities that combine innovative technology, marketing opportunities and expert support services to the Company's independent and home-based travel agents. With Joystar, experienced and new travel agents can concentrate on promoting travel and creating client loyalty without the administrative and financial burden of owning/operating a traditional storefront travel agency.
"Forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 may be included in this news release. These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future events or results. Joystar, Inc. disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. Please refer to the documents filed by Joystar, Inc. with the Securities and Exchange Commission, which identify important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to risks associated with our ability to (i) increase revenues, (ii) obtain profitability, and (iii) obtain additional financing, changes in general economic and business conditions (including in the online business and financial information industry), actions of our competitors, the extent to which we are able to develop new services and markets for our services, risks in connection with acquisitions, the time and expense involved in such development activities, the level of demand and market acceptance of our services and changes in our business strategies.
Additionally, forward-looking statements concerning the performance of the travel and leisure industry are based on current market conditions and risks, which may change as the result of certain regulatory, political or economic events, a shift in consumer travel preferences, as well as those risks and uncertainties described in the Company's filings with the Securities and Exchange Commission, which could cause actual events or results to differ materially from the events described in the forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on these forward-looking statements.
SOURCE: Joystar, Inc.
TGEN News Targeted Genetics Strengthens Intellectual Property for AAV Vector Manufacturing Processes
Business Wire - February 10, 2006 07:30
SEATTLE, Feb 10, 2006 (BUSINESS WIRE) -- Targeted Genetics Corporation (Nasdaq:TGEN) today announced the issuance of an additional patent related to its adeno-associated virus (AAV) vector manufacturing processes. U.S. patent #6,995,006 is titled, "Methods for generating high titer helper-free preparation of released recombinant AAV vectors." The patent describes an AAV manufacturing process in which numerous growth conditions used to culture the production cells are controlled in a manner that leads to the release of AAV vector particles into the cell culture medium without the need for breaking open the host cell membrane. This release of vector into the media leads to improved production quality and allows for a more cost-effective approach to large-scale manufacturing of AAV vectors. Targeted Genetics' growing body of intellectual property related to AAV manufacturing supports several of the Company's product development programs, including its inflammatory arthritis, HIV/AIDS vaccine and congestive heart failure programs.
"The issuance of Targeted Genetics' latest patent further strengthens our leadership position in the field of AAV manufacturing," said Barrie J. Carter, Ph.D., Executive Vice President and Chief Scientific Officer of Targeted Genetics. "This patent covers numerous growth conditions that support the release of AAV vectors into the media. Most AAV harvesting procedures require breaking open the cells in which the vector particles have been produced. This leads to significant levels of contamination, which must then be purified away from the vector particles, requiring an additional and timely step in the manufacturing process. Many of the techniques used to remove these contaminants also trap AAV vector particles, reducing the overall efficiency of the manufacturing process. Under the growth conditions described in this patent, AAV vector particles are released into the cell culture medium in which the producer cells are grown without rupturing the cell membranes. Notably, this release of vector particles allows for vector harvesting procedures that are readily scalable to meet commercial needs, and eliminates contaminants that may occur at significant levels with other vector harvest methods."
The combined attributes of persistent expression and a good safety profile make AAV vectors the vector of choice for developing gene-transfer treatments for a wide variety of chronic disease and the development of viral vaccines. Most AAV production procedures result in AAV vectors being retained inside the producer cells. Under the growth conditions described in this patent, AAV vectors are released from intact cells into the media similarly to the release of recombinant proteins or monoclonal antibodies. Using the growth conditions described in this patent, AAV vectors are harvested from the cell culture supernatant by standard biopharmaceutical methods that are scalable and cost effective. The ability to retain intact cells leads to a harvest that is significantly reduced in contaminants and allows Targeted Genetics to purify AAV vector particles from AAV manufacturing production components by a series of scalable, cost effective chromatography columns. This method can be utilized with any rAAV vector production method including Targeted Genetics' proprietary cell line or hybrid virus technologies, and is expected to support more effective and streamlined production processes.
"Targeted Genetics AAV manufacturing competence continues to fuel our ability to attract strategic partners, enabling us to undertake and aggressively advance our product development efforts in inflammatory arthritis, HIV/AIDS, congestive heart failure and Huntington's disease," said H. Stewart Parker, President and Chief Executive Officer. "Importantly, the methods described in this patent enable manufacturing procedures designed to improve costs, scalability and purification, which are critical for the commercialization of our innovative product pipeline."
About Targeted Genetics
Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative targeted molecular therapies for the prevention and treatment of inflammatory arthritis, HIV/AIDS and other acquired and inherited diseases with significant unmet medical need. Targeted Genetics uses its considerable knowledge and capabilities in the development and manufacturing of gene delivery technologies to advance a diverse product development pipeline. Its product development efforts target inflammatory arthritis, HIV/AIDS, congestive heart failure, Huntington's disease, and hyperlipidemia. To learn more about Targeted Genetics, visit its website at www.targetedgenetics.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements regarding our intellectual property, research programs and clinical trials, our manufacturing process, and our product development platforms including AAV vectors, our ability to develop and commercialize our product candidates, our ability to attract strategic partners and other statements about our plans, objectives, intentions and expectations. In particular, the statements regarding the Company's pipeline and potential application of this patent to any future product candidates are forward-looking statements. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect its actual results include, but are not limited to, our ability to obtain, maintain and protect our intellectual property, our ability to raise capital when needed, our ability to recruit and enroll suitable trial participants, the timing, nature and results of research and clinical trials, potential development of alternative technologies or more effective processes by competitors, and, our ability to obtain and maintain regulatory or institutional approvals, as well as other risk factors described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in Targeted Genetics' Quarterly Report on Form 10-Q for the quarter ended September 30, 2005. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change expectations.
SOURCE: Targeted Genetics Corporation
Targeted Genetics Corporation
Stacie D. Byars, 206-521-7392
Copyright Business Wire 2006
--------------------------------------------------------------------------------
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
INMR- News - Data Indicate That Whole-Inactivated HIV-1 Immunogen Induces HIV-Specific Immune Responses in HIV-Infected, HAART-Naive Patients; Final Data from IMNR.OB's Italian Study Presented in Poster at CROI Annual Meeting
Business Wire - February 10, 2006 07:00
CARLSBAD, Calif., Feb 10, 2006 (BUSINESS WIRE) -- The Immune Response Corporation (OTCBB:IMNR) announced today that the final results from a Phase II clinical study indicate that the Company's whole-inactivated HIV-1 immunogen induces HIV-specific immune responses in HIV-infected, antiretroviral drug-naive patients. Specifically, this original formulation product showed potential to stimulate key immunologic parameters and to stabilize the loss of CD4+ cells, which could help prolong the time before these patients need to initiate antiretroviral therapy. The poster was presented at this week's 13th Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.
"CD4+ counts may be an especially important marker of disease progression and we plan to build on this data with our most potent clinical candidate, IR103," noted Joseph O'Neill, M.D., President and Chief Executive Officer of The Immune Response Corporation. "We have two ongoing clinical studies that will investigate IR103 in the drug-naive patient population. We will be expanding them and look forward to reporting the findings."
The analysis included data from 49 patients that completed the study, and showed that median absolute CD4+ cell counts remained stable through week 28 in the patients that received three injections of the HIV-1 immunogen but declined in both the IFA and saline groups. The HIV-1 immunogen's effect on immune reconstitution was evidenced by an augmented production of factors known to reduce HIV replication, such as beta chemokines and alpha defensin. These data suggest a possible mode of action via boosting the body's own defense against HIV, which could play a role in delaying the initiation of antiretroviral therapy.
The multi-center, single-blind, randomized study followed a total of 51 patients over 28 weeks following treatment with the Company's patented HIV-1 immunogen, IFA or saline. Patients were antiretroviral-therapy naive and had HIV RNA levels between 10,000 and 40,000 copies/mL and CD4+ counts between 400 and 800 cells/uL at study entry. Patients received three injections of the HIV-1 immunogen (n=19), IFA (n=10), or saline (n=11) at weeks 0, 12, and 24. A fourth group received only a single injection of the HIV-1 immunogen at week 0 (n = 11). Although minor adverse events were reported, no treatment-limiting toxicities have been recorded to date.
This trial was intended to explore the potential utility of the HIV-1 immunogen and was not designed to have enough statistical power to be used for regulatory approval. The Company is planning a clinical program that would use the data from this and other trials to design IR103 trials in the near future. The HIV-1 immunogen and IR103 are not approved by any regulatory agencies in any country at this time.
About IR103
More than 25 million people have died since human immunodeficiency virus (HIV) was first recognized in 1981 (source: UNAIDS, December 2005), and the new infection rate continues to grow at an alarming rate. Despite medical advances, the worldwide pandemic continues to claim more than 3.1 million lives each year (source: UNAIDS, December 2005). Additional safe and effective treatments are desperately needed.
IR103 is a second-generation HIV immunotherapy based on the Company's patented whole-inactivated virus technology, which was co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of the Company's HIV-1 immunogen (REMUNE(R)), the Company's first generation HIV product candidate. Preclinical research and recent clinical data show that IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. This product differs from currently available antiretroviral drug therapies since it is designed to stimulate an HIV-infected individual's immune system to fight the virus.
The Company recently completed the first part of a 49-patient Phase I/II five-arm, randomized, single-blind, controlled, multi-center clinical study of safety and bioactivity of IR103 in HIV patients on HAART (highly active antiretroviral therapy) at sites in the United Kingdom and Canada, and plans to report new data as they become available later this year. Preliminary results of this trial, reported last year, indicate that IR103 is safe, induces HIV-specific immune responses and greatly enhances IFN-gamma and RANTES mRNA. IFN-gamma and RANTES are considered immune system markers that give an estimate of the robustness of the immune response generated by IR103 in patients.
The second part of this study, along with another similar study in Italy, will investigate IR103 as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines. These studies, which the Company plans to expand, will ultimately enroll over 200 drug naive patients. Along with tracking safety and measuring HIV-specific immune responses, these studies will assess IR103's ability to affect patients' CD4+ counts. CD4+ count is a critical marker of HIV disease progression that is used, along with viral load, to determine when a patient should begin antiretroviral therapy. The Company believes an immune-based therapy that could stabilize CD4+ counts could be used to delay initiation of antiretroviral therapy and serve as an important advance in the treatment of HIV. Final data from a drug-naive patient Phase II Italian study of REMUNE(R) showed that median absolute CD4+ cell counts of patients that received three injections of the Company's first generation immunotherapy remained stable through week 28, while declining in patients in the placebo groups. The Company believes that the increased potency of IR103 could translate to a more durable and pronounced effect on CD4+ counts.
About The Immune Response Corporation
The Immune Response Corporation (OTCBB: IMNR.OB) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of multiple sclerosis (MS) and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
NeuroVax(TM), which is based on the Company's patented T-cell receptor (TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax(TM) has been shown to stimulate strong disease specific cell mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific
findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn's disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the FDA for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis.
IR103 is based on the Company's patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE(R), the Company's first generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. The Company is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.
Please visit The Immune Response Corporation at www.imnr.com
This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of NeuroVax(TM) or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax(TM) or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials. A more extensive set of risks is set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2004, and its subsequent Quarterly Reports filed on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation.
SOURCE: The Immune Response Corporation
The Immune Response Corporation
Investor Contact:
Michael K. Green, 760-431-7080
info@imnr.com
or
Sam Brown Inc.
Media Contact:
Laura Silver, 323-848-2051
silver@sambrown.com
Copyright Business Wire 2006
--------------------------------------------------------------------------------
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
Qoil - NewsQuest Oil Enters Participation Agreement for Barnett Shale Horizontal Well; Quest Management Provides Additional Updates
Business Wire - February 09, 2006 13:20
HOUSTON, Feb 09, 2006 (BUSINESS WIRE) -- Quest Oil Corporation (OTCBB:QOIL), is pleased to announce the Company has entered into a joint venture participation agreement for an interest in the Odom (Martin) Ranch No. 1H horizontal well on the Martin-Hyponex prospect from Gaither Petroleum. The well spudded on February 5th 2006 in Parker County. Participants in the well are Sauder Management Company (Operator), Carrizo Oil and Gas Inc. (NASDAQ:CRZO), Triad Oil and Gas, L.L.C. and Ryder Scott, LP. The well is in the Newark East Field (Barnett Shale) in Southeast Parker County close to the Hood County border.
The participation marks our official entry into the Barnett Shale play and enables Quest to secure significant amount of good quality 3D seismic data that comes with this acquisition. The "Odom (Martin) No.1" will take approximately 25 days drill to TVD of 6,200 ft. and MD of 9,500 ft. Quest is using this as a springboard to look at several other opportunities in the Barnett Shale area.
Bill Stinson, Quest Oil Corporation's COO said, "Having the opportunity to participate in ventures with solid industry partners like Gaither Petroleum, Sauder Management, Carrizo and Ryder Scott is one of the main components in expanding our business strategy. Carrizo has extensive experience in the Barnett Shale and some of the best operations people I've worked with. Carrizo drilled several successful Barnett Shale wells in the area and we expect this well to be no different. Last weeks NAPE conference was very informative in terms of what acreage is available even in the hot Barnett leasing areas like Bosque, Hill and Erath counties."
Acadia North 3D Seismic
Stinson commented, "Acadia 3D processing is nearing completion and the preliminary unmigrated stacks are excellent. Based on what I've seen so far, there are some unusual things in the data that may form the basis for another distinct play. It's subtle and without 3D seismic to define the geometry, one would likely completely miss the opportunity with blind infill drilling."
Hawkeye - Midkiff
According to Stinson, "The Hawkeye/Midkiff area has produced a few surprises. We're getting a lot more oil production from some wells on the Johnson lease than we expected. A review of the production history has revealed that a significant amount of gas has been produced. In the past, this gas has been flared mainly because of the low gas prices at the time. We are looking into the possibility of tying this gas production into the main line. Preliminary indications are that this gas is commercial and can contribute a significant amount of revenue."
ABOUT QUEST OIL CORPORATION
The Company is committed to the exploration and development of economical oil and natural gas reserves globally. Quest management is focused on an acquisition program targeting high quality and low risk prospects. Initially Quest is focused on the development of North American oil and gas resources allowing highly leveraged production opportunities in Alberta and Texas, through its 100% owned subsidiaries Quest Canada Corp. and Wallstin Petroleum LLC and PetroStar Oil Services, Inc.
ON BEHALF OF THE BOARD
Quest Oil Corporation. "Cameron King" Cameron King MBA - President and CEO Director
To find out more about Quest Oil Corporation (OTCBB:QOIL), visit our website at www.questoil.com.
Safe Harbor for Forward-Looking Statements:
Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to acquire and develop specific projects, the ability to fund operations and changes in consumer and business consumption habits and other factors over which Quest Oil Corporation has little or no control. All persons considering an investment in Quest Oil Corporation are encouraged to consult with an investment professional and to review Quest's public filings which are available at www.sec.gov.
SOURCE: Quest Oil Corporation
Quest Oil Corporation
Mr. Darren Hayes, Corporate & Business Development
Toll Free: 1-866-264-7668
Fax: 1-800-608-3562
dhayes@questoil.com
Copyright Business Wire 2006 ********************************************************************** As of Sunday, 02-05-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 01-20-2006 for CRZO @ $26.71. (C) 2006 Comtex News Network, Inc. All rights reserved.
--------------------------------------------------------------------------------
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
XDSL News- mPhase Technologies' Nanobattery Achieves Breakthrough in Portable Power; Joint development with Lucent Technologies Bell Labs yields the first fully assembled working nano-based battery prototype
Business Wire - February 09, 2006 13:07
LITTLE FALLS, N.J. & MURRAY HILL, N.J., Feb 09, 2006 (BUSINESS WIRE) -- mPhase Technologies (OTCBB:XDSL) and Lucent Technologies Bell Labs (NYSE:LU) today reported that their jointly developed nano-based "smart" battery prototype has proven it can store and convert energy on demand. This practical confirmation of the theory behind the technology is a major milestone in the product development process.
In a test conducted at Bell Labs' Murray Hill, N.J. facility, the development team demonstrated that the first fully assembled prototype device could generate enough power on demand to light a light-emitting diode (LED). The prototype is based on a novel nanostructured architecture pioneered at Bell Labs.
"We are pleased that the mPhase-Bell Labs team has surmounted many technical obstacles to make this theory into a working prototype," said Ron Durando, CEO mPhase Technologies. "This reinvention of the battery is addressing a major market need for portable, programmable power."
The demonstration, including the lighting of the LED, was captured on video by a production team from ScienCentral, a service that provides video reports on scientific breakthroughs to TV stations and the general public. The footage is viewable at: http://www.sciencentral.com.
The new generation of reserve power cells is based on a Bell Labs discovery that electrolyte will stay atop nano-textured surfaces until stimulated to flow, thereby triggering a reaction producing electricity. The "electrowetting" process in effect can permit activation of the batteries when required, yielding a very long shelf life. Batteries based on this technology have the potential to deliver far longer shelf life than existing battery technology.
About mPhase Technologies, Inc.
mPhase Technologies Inc. (OTC: XDSL) develops and commercializes next-generation telecommunications and nanotechnology solutions, delivering novel systems to the marketplace that advance functionality and reduce costs. The company, awarded the 2005 Frost & Sullivan Excellence in Technology Award and the Nano 50 Award from NASA Nanotech Briefs, is bringing nanotechnology out of the laboratory and into the market with a planned innovative long life power cell. Additionally, the company is working on prototype ultra-sensitive magnetometers that promise up to a 1,000-fold increase in sensitivity as compared with available uncooled sensors. More information is available at the mPhase Web site at www.mPhaseTech.com
About Bell Labs and Lucent Technologies
Bell Labs is the leading source of new communications technologies. It has generated more than 30,000 patents since 1925 and has played a pivotal role in inventing or perfecting key communications technologies, including transistors, digital networking and signal processing, lasers and fiber-optic communications systems, communications satellites, cellular telephony, electronic switching of calls, touch-tone dialing, and modems. Bell Labs scientists have received six Nobel Prizes in Physics, nine U.S. National Medals of Science and eight U.S. National Medals of Technology. For more information about Bell Labs, visit its Web site at www.bell-labs.com.
Lucent Technologies designs and delivers the systems, services and software that drive next- generation communications networks. Backed by Bell Labs research and development, Lucent uses its strengths in mobility, optical, software, data and voice networking technologies, as well as services, to create new revenue-generating opportunities for its customers, while enabling them to quickly deploy and better manage their networks. Lucent's customer base includes communications service providers, governments and enterprises worldwide. For more information on Lucent Technologies, which has headquarters in Murray Hill, N.J., USA, visit www.lucent.com.
Safe Harbor Statement
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies mentioned in this press release in light of current conditions, expected future developments and other factors they believe to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
SOURCE: mPhase Technologies
Media:
TMI
Sam Gronner, 201-592-7896
sam@technovative.com
or
Investors:
CEOCast
Ken Sgro, 212-732-4300
or
Lucent Technologies
Peter Benedict, 908-582-7710 (office)
pbenedict@lucent.com
Copyright Business Wire 2006 ********************************************************************** As of Sunday, 02-05-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 10-27-2005 for LU @ $2.79. (C) 2006 Comtex News Network, Inc. All rights reserved.
--------------------------------------------------------------------------------
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
IMNR up 42%
Hey Good Mourning Stockx,
SSTU up 17.39%
UPDA - News - West Oil & Gas, Inc. Reviewing First Well Recompletion Proposal In Utah
Business Wire - February 09, 2006 10:01
SALT LAKE CITY, Feb 09, 2006 (BUSINESS WIRE) -- Universal Property Development and Acquisition Corporation (OTCBB:UPDA) subsidiary, West Oil & Gas, Inc., has entered into negotiations with Homeland Gas and Oil, Inc. of Roosevelt, Utah for a well recompletion venture which is slated to be undertaken in Uintah County, Utah.
This project will be similar to other successful efforts in the same township and will include running new casing, well site refurbishment, logging, frac type stimulation and setting of a new Rotoflex Pumping Unit on the well known as the Ute 1-16 A1E.
Homeland Gas and Oil, Inc. (HGO) has numerous opportunities for both recompletions and step out drilling in the Bluebell/Altamont area. Homeland's "Stock in Trade" is solid prospective properties that have been under utilized. As prices for oil and gas have continued to rise, these properties have become more and more attractive and desirable. As indicated by Bob Ballou, Homeland Geologist, "this is an outstanding prospect with tremendous upside potential."
A mutually acceptable agreement for the venture will be entered into by all of the participants, including HGO and Landmark 4 LLC. An Area of Mutual Interest (AMI) will be established and the venture will be managed and operated by HGO.
Once the agreement is signed by all of the participants, the project will be funded for the estimated total cost amount of $863,310.00 and the funds put in escrow. HGO will draw on AFE funds for actual costs associated with the project. HGO management duties will include the following:
-- Preparation of a detailed chronological prognosis and task list.
-- Preparation of all sundry notices and notification to all State, Tribal and Federal entities.
-- Coordination of and preparation for the actual work being preformed.
-- Setting up a COPAS approved accounting system for the project as determined by the operating agreement, and determining a mutually agreed to notification system to inform all partners of every facet of the daily work, subsequent production and day to day LOE costs.
Baring any unforeseen weather problems, following the signing of the agreement preparations for the project should conclude within three weeks time. Actual time from start of workover to establishing production is anticipated to be 3-4 weeks in duration.
About UPDA
Universal Property Development and Acquisition Corporation (OTCBB:UPDA) focuses on the acquisition and development of proven oil and natural gas reserves and other energy opportunities through the creation of joint ventures with under-funded owners of mineral leases and cutting-edge technologies.
For additional information visit: www.universalpropertydevelopment.com.
Statements contained in this press release that are not based upon current or historical fact are forward-looking in nature. Such forward-looking statements reflect the current views of management with respect to future events and are subject to certain risks, uncertainties, and assumptions. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, or described pursuant to similar expressions.
SOURCE: Universal Property Development and Acquisition Corporation
Universal Property Development and Acquisition
Corporation
Bradford Moore, 561-630-2977
info@updac.com
Copyright Business Wire 2006
--------------------------------------------------------------------------------
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
HDVY new Patent
CVAS _ News -Canadian Government selects CVAS to provide Electronic Security Solutions
Business Wire - February 09, 2006 08:30
WHITBY, Ontario, Feb 09, 2006 (BUSINESS WIRE) -- Creative Vistas, Inc., (CVAS) announced today that its subsidiary AC Technical Systems Ltd. had been awarded a project to integrate security and surveillance systems by the Canadian Provincial Government of Ontario. A major component of the project is to integrate security and surveillance systems within multiple locations across the Province of Ontario. As part of the project AC Technical Systems is expected to provide its integrated security solutions for over 85 physical locations.
"We are pleased that we continue to win additional projects to service and integrate technically advanced security and surveillance systems within our high profile customer base" said Sayan Navaratnam, Chief Executive Officer of Creative Vistas, Inc. AC Technical Systems will design, supply and install Video and Audio equipment as part of the project.
"We continue to see strong demand for our technologically advanced security solutions from our existing customers as well as potential new customers" said Dominic Burns, President of AC Technical Systems. Substantial portions of the project are expected to be completed within the next six months."
Creative Vistas, Inc. is a leading provider of advanced security and surveillance products and solutions. It also provisions the deployment and servicing of broadband technologies to the commercial and residential market. It primarily operates through its wholly-owned subsidiaries AC Technical Systems Ltd and Iview Digital Video Solutions Inc, to provide integrated electronic security and surveillance systems and technologies. It provides its systems to various high profile clients including: Government, School Boards, Retail Outlets, Banks, and Hospitals. The Company operates through its subsidiary Cancable Inc. to provision the deployment of broadband technologies to the commercial and residential market. The Company has offices in Ontario, Canada.
Forward-Looking Statements: Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Securities Litigation Reform Act of 1995. The Company's actual results could differ materially from expected results for reasons described from time to time in the Company's public filings. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.
SOURCE: Creative Vistas, Inc.
Creative Vistas, Inc.
Sayan Navaratnam, 905-666-8676
Copyright Business Wire 2006
--------------------------------------------------------------------------------
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
Mourning All
CGCP - News -Cardiogenesis Announces Successful Clinical Application of PHOENIX TMR Plus Stem Cell Delivery System
PR Newswire - February 09, 2006 07:30
PHOENIX Revascularization System Directs Precise Biologic Delivery Into Holmium: YAG TMR Stimulated Tissue
FOOTHILL RANCH, Calif., Feb 09, 2006 /PRNewswire-FirstCall via COMTEX/ -- Cardiogenesis Corporation (OTC Bulletin Board: CGCP), the market leader in surgical products and accessories used in angina-relieving Transmyocardial Revascularization (TMR) and Percutaneous Myocardial Channeling (PMC) procedures announced today the first clinical surgical cardiac revascularization procedure completed on January 25, 2006 by Dr. Wan Feng, Chairman of the Department of Cardiac Surgery at The People's Hospital of Beijing University with its PHOENIX Revascularization Delivery System for precise delivery of stem cells in conjunction with Holmium: YAG TMR.
Chairman and CEO, Michael J. Quinn commented, "There is exciting clinical potential for precise biologic delivery to the Holmium:YAG thermoacoustic stimulated tissue zone surrounding the TMR channels at the time of cardiac surgery. The PHOENIX Delivery System is a priority development program for the Company, which we expect to implement with both our surgical and percutaneous Holmium:YAG laser myocardial revascularization platforms. We are focused on verifying the surgical safety and feasibility with Dr. Wan and other targeted centers around the world as we understand more about the application stem cells and other biologics to increase and optimize the physiologic benefits of our therapy."
Mr. Quinn continued, "We are encouraged by the positive feedback received from Dr. Wan and his team regarding the first clinical case with the PHOENIX Revascularization Delivery System. His feedback confirms that we are on the right track in delivering the correct advanced tools to surgeons striving to provide the optimal combination of therapies during a surgical procedure to patients suffering from severe cardiovascular disease. This advanced tool combines the precise delivery of stem cells or other biologic and pharmacologic therapy to the thermoacoustic stimulated tissue zone surrounding the Holmium:YAG TMR channels."
The procedure combined the off-pump coronary artery bypass grafting, with implantation of autologous stem cells in conjunction with transmyocardial revascularization (TMR) using the PHOENIX Revascularization System. The patient is a 77 year old female suffering from chest pain related to an acute myocardial infarction. Angiography confirmed severe three vessel disease. In preparation for the procedure, 5 ml of stem cells were derived from the patient's bone marrow. Following the off pump heart bypass through a median sternotomy, the TMR channeling and implantation of stem cells in and around the channels was performed using the Cardiogenesis PHOENIX Revascularization System (the TMR Holmium:YAG laser and PHOENIX Revascularization Delivery System) in all ischemic regions and the infarct zone.
Dr. Wan stated, "We utilize advanced surgical techniques to provide enduring patient benefits while minimizing the risk and morbidity of the procedure. This advanced procedure combined bypass grafting to the anterior and posterior regions of the heart while delivering TMR plus stem cells to areas of the heart muscle that could not be bypassed. The PHOENIX Revascularization Delivery System provided precise and efficient cell implantation into and around the TMR channels."
Dr. Wan has performed over 400 adjunctive TMR procedures to date. His understanding that the thermoacoustic energy wave of Holmium:YAG TMR stimulates tissue around the laser channels promoting angiogenesis motivated him to apply the laser therapy with stem cells in areas of the heart that could not be bypassed. He has treated 20 patients with the combination procedure to date using separate sterile syringe application of stem cells after completing TMR channels in the targeted areas.
Dr. Wan explained, "As Holmium:YAG TMR has been shown to stimulate microvascular growth in the tissue surrounding the laser channel, our goal in this advanced combination procedure is to target the delivery of stem cells to the thermoacoustic stimulated area of new vessel growth surrounding the Holmium: YAG laser channels. This stimulated tissue zone signals the body's healing system to deliver stem cells, and our goal is to increase the vascular response and clinical benefit by delivering a large volume of the patients own stem cells to the targeted area during the initial stages of angiogenesis."
He continued, "The safety and feasibility of autologous stem cell therapy in the treatment of advanced cardiac disease is well documented. There is exciting potential of stem cells in providing improved long-term outcomes in cardiac patients. The PHOENIX Revascularization System addresses the need for precise, targeted cell delivery. We expect to optimize uptake and activation of these potent cells by targeting the Holmium:YAG thermoacoustic energy stimulated tissue zone at the time of surgery. Ultimately, we hope to see improved function in all areas of his heart, including the infarct area."
"The early outcome of this procedure was favorable, with the patient in recovery with no arrhythmia," stated Dr. Wan. "This advanced combined procedure utilizing the PHOENIX Revascularization System represents a worldwide first, and we intend to perform further evaluation for clinical safety and feasibility of this technique utilizing this advanced combination device."
About Cardiogenesis Corporation
IGTG - News -Ingen Technologies, Inc. Secure Balance(TM) Reaches the Consumer Markets
PR Newswire - February 09, 2006 07:15
- Secure Balance(TM) at AAN With 8,000 Neurologists -
CALIMESA, Calif., Feb 09, 2006 /PRNewswire-FirstCall via COMTEX/ -- Ingen Technologies, Inc. (OTC: IGTG), a medical device manufacturer of OxyAlert(TM), OxyView(TM), and Secure Balance(TM), announces that the company's Secure Balance(TM) products will be televised on major news stations to millions of consumers throughout the United States and abroad.
The Secure Balance(TM) products are gaining increasing public awareness through direct advertising, workshops and trade shows. Max World News TV is filming this weekend in Jacksonville-Florida where the company has a major Secure Balance(TM) workshop. The filming will be used to develop a major news story about the benefits of Secure Balance(TM) and how it provides a healthier lifestyle for people, and at the same time saves millions of dollars with our Federal Health & Welfare budget.
The company is also scheduled to exhibit Secure Balance(TM) in San Diego at the 2006 - Annual Meeting of the American Academy of Neurology (AAN). The American Academy of Neurology (AAN) provides valuable resources for medical specialists worldwide who are committed to improving the care of patients with neurological diseases. The AAN's nearly 19,000 members look to the AAN for the most comprehensive professional development, career enhancement, and practice improvement opportunities available. More than 8,000 neurologists are expected to attend this four day event.
"The Secure Balance(TM) products have made solid inroads among neurologists, chiropractors and physical therapists. There is a $400M neurology market, and the $500M Chiropractic market. We have a strong attendance at our next clinical workshop, and we average about 15 new leads per week," said Scott Sand, Chairman & CEO.
About Ingen Technologies, Inc.
Ingen Technologies, Inc. is a public company trading under NASDAQ OTC:IGTG, which has been in business since 1999. IGTG is a medical device manufacturer and a growth-oriented company that owns US patent(s), trademarks, and proprietary medical products.
The Company's flagship product is OxyAlert(TM), a second-generation design of the Company's BAFI(TM) product line. Both of these products have been issued two US Patents: Patent No. 6,137,417 issued on October 24, 2000 and Patent No. 6,326,896 issued on December 4, 2001. Both of these products are low-oxygen safety warning devices used on remote oxygen cylinders for patients, commercial aircraft, military transport, and fire and safety equipment. OxyAlert(TM) technology encompasses the use of digital sensing and RF frequency transfer so that care givers can access a hand-held remote to monitor the actual oxygen level of any oxygen cylinder at a reasonable distance.
The newest product, OxyView(TM), has a patent pending, and is a pneumatic gauge that provides visual safety warning of oxygen flow for patients in the hospital, surgical room, outpatient therapy, nursing homes and emergency response facilities. This product enhances the safety, assurance and accuracy of patients being administered oxygen from any source. OxyView(TM) is a lightweight pneumatic gauge that is attached to the oxygen tubing just below the neck. It informs the nursing staff of the oxygen flow rate near the patient. It could quickly inform the physician or technician of any leak or inaccuracy between the delivery source and the patient.
The Secure Balance(TM) product is a private-label product that includes a vestibular function testing system and balance therapy system. The vestibular function testing system is manufactured by Interacoustics LTD. in Denmark and is referred to as the VNG. The balance therapy system is manufactured by SportKAT(R), Inc. in San Diego, California. The Secure Balance(TM) program provides equipment, education and training about balance and fall prevention to physicians and clinicians worldwide.
The Pure Produce(TM) product is a continuing research & development program currently under design. This program uses hydroponics technology to grow various plants without the use of soil, fertilizer and water consumption. The Company anticipates entering the nutriceutical and pharmaceutical markets over the next two years.
"Our team of professionals has developed our medical products for the ever-increasing elderly population. Our products are superior to any of our competition and they allow for effective medical product availability to seniors, and at the same time the increasing senior population allows for a steady growth in sales and profits," said Scott Sand, CEO & Chairman of Ingen Technologies.
For more information, visit www.ingen-tech.com
Investor Relations Contact: Scott R. Sand, C.E.O. & Chairman
Ingen Technologies, Inc. - Administrative Office
35193 Avenue "A", Suite-C
Yucaipa, California 92399
Phone: (800) 259-9622 or (909) 790-7180
Fax: (800) 777-1186 or (909) 795-6340
Email: Info@ingen-tech.com
A Member of the Better Business Bureau
A Member of the Chamber of Commerce
A Licensed Business in the City of Yucaipa
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements that are made pursuant to "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
SOURCE Ingen Technologies, Inc.
Scott R. Sand, C.E.O. & Chairman of Ingen Technologies, Inc., +1-800-259-9622, or
+1-909-790-7180, or fax, +1-800-777-1186, or fax +1-909-795-6340, Info@ingen-tech.com
http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
--------------------------------------------------------------------------------
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
PAIM- I don't think that split is till next week
PAIM NEWS - Pearl Asian Mining Industries: Significant Gold and Silver Deposits Discovered at the XYZ Gold Mine: Geologist Recoverable Yield Estimate 1.5 Million Tons, an Average Grade of 6.34 Grams/Ton Gold (AU) and 37.24 Grams/Ton Silver (AG) in 20
TGAL NEWS Tegal Receives Repeat Order for Multiple ACS900 Series Etch Systems From Leading Wireless Component Supplier
Business Wire - February 08, 2006 09:30
PETALUMA, Calif., Feb 08, 2006 (BUSINESS WIRE) -- Tegal Corporation (Nasdaq:TGAL) today announced that a leading wireless component supplier has placed a multiple system order for 901ACS diode plasma etch systems featuring the Advanced Control System. The three new systems, valued at over $1 million, will expand this supplier's existing production capacity in gallium arsenide (GaAs) semiconductors, which are widely used in wireless communications products. The last multiple system order from this customer occurred in July of 2004, and was based on the excellent performance of the Tegal 901 tools currently on-site, along with Tegal's technical support and experience in etching specialty materials on non-standard substrates.
"The wireless industry is recovering and driving our sales across all product lines," said Murali Narasimhan, Tegal's Vice President of Marketing. "We are committed to continuously improving our offerings to producers of wireless components, and to making our capabilities known to a larger group of potential customers. We are very pleased to be rewarded with this repeat order from an important customer."
The Tegal 901ACS is among the latest in a series of diode plasma etch systems produced by Tegal for companies around the world. Over 1,500 systems have been shipped and continue to provide reliable and cost-effective support for a wide range of processes. The Tegal 900ACS series is intended for a wide variety of applications, including pad, zero layer, non-selective nitride, backside and planarization, as well as oxide, nitride, poly and compound materials applications, such as GaAs. The platform incorporates a production-proven transport system that can accommodate 75 mm to 200 mm round, square or rectangular substrates.
The ACS upgrade is available exclusively from Tegal as a field or factory retrofit for the existing installed base of 900 and 980 series systems. It features a fully integrated graphical user interface, parametric data logging, full factory automation support, and throughput enhancements for the wafer-handling system. For information on the 900 series ACS upgrade package, please contact your local Tegal representative or email info@tegal.com.
Safe Harbor Statement
Except for historical information, matters discussed in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements, which are based on assumptions and describe our future plans, strategies and expectations, are generally identifiable by the use of the words "anticipate," "believe," "estimate," "expect," "intend," "project" or similar expressions. These forward-looking statements are subject to risks, uncertainties and assumptions about the Company including, but not limited to industry conditions, economic conditions, acceptance of new technologies and market acceptance of the Company's products and services. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements in this paragraph. For a further discussion of these risks and uncertainties, please refer to the Company's periodic filings with the Securities and Exchange Commission.
About Tegal
Tegal provides process and equipment solutions to leading edge suppliers of advanced semiconductor and nanotechnology devices. Incorporating unique, patented etch and deposition technologies, Tegal's system solutions are backed by over 35 years of advanced development and over 100 patents. Some examples of devices enabled by Tegal technology are energy efficient memories found in portable computers, cellphones, PDAs and RFID applications; megapixel imaging chips used in digital and cellphone cameras; power amplifiers for portable handsets and wireless networking gear; and MEMS devices like accelerometers for automotive airbags, microfluidic control devices for ink jet printers; and laboratory-on-a-chip medical test kits.
More information is available on the Internet at: www.tegal.com.
SOURCE: Tegal Corporation
Tegal Corporation
Murali Narasimhan, 707-763-5600
or
Nagle & Ferri Investor Relations
Frank Nagle or Bob Ferri, 415-575-1999
Copyright Business Wire 2006 ********************************************************************** As of Saturday, 02-04-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 08-15-2005 for TGAL @ $0.69. (C) 2006 Comtex News Network, Inc. All rights reserved.
--------------------------------------------------------------------------------
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
DLGI - News; DataLogic International Secures 5,000 Unit Order With GPS Fleet Tracking Provider SecuraCom GPS(TM)
PR Newswire - February 08, 2006 08:37
IRVINE, Calif., Feb 08, 2006 /PRNewswire-FirstCall via COMTEX/ -- DataLogic International, Inc., (OTC Bulletin Board: DLGI; Berlin, Frankfurt Stock Exchange: 779612), a provider of GPS-based mobile asset tracking, secured mobile communications and network security, today announced that GPS fleet tracking provider SecuraCom GPS has entered into an OEM manufacturing agreement with DataLogic International to fill its growing need for a reliable multi-functional GSM/GPRS solution.
Under the terms of the agreement, SecuraCom GPS will purchase 5,000 GPS tracking devices appropriately called BigBrother(TM) and associated airtime. The BigBrother GPS units, built to the product specifications of SecuraCom GPS and airtime will be delivered during the 2006 calendar year and are currently available as part of the SecuraCom GPS fleet tracking solution.
SecuraCom GPS CEO Gary Ryan said, "After testing and reviewing several GSM products by various manufacturers, the decision to award this contract to DataLogic was based on a number of factors including consistency of product performance, competitive pricing and excellent product and customer support. We look forward to working with DataLogic to further enhance our presence and reputation for high quality and reliability in this rapidly growing marketplace."
Keith Moore, Chairman and CEO of DataLogic International commented, "We are excited to be working with SecuraCom GPS and look forward to a long and successful business relationship. SecuraCom GPS' decision to embrace DataLogic as its primary GPS solutions provider is further evidence of our commitment to quality, value and customer service. We believe 2006 will be a break out year for the GPS industry and we believe we are well positioned to meet the needs of this growing market. The agreement with SecuraCom GPS is a great start for DataLogic for 2006 and we look to continue to build upon our sales momentum throughout the year."
BigBrother is an integrated GPS location-tracking device with onboard wireless communication that utilizes industry standard communication methods. The device is designed to be discreetly installed to avoid detection and can be customized for most vehicle and mobile asset tracking applications. Expandable multiple input/output interfaces allow for monitoring such items as doors opening/shutting and power takeoff engagements. Output interfaces allow for locking/unlocking doors or disabling/enabling ignition and other client specific needs. The SecuraCom GPS BigBrother is distributed solely through SECURACOM GPS and its affiliate distributors and dealers internationally.
I'm a newbie, don't know enough to give an opinion, but that chart looks like it's bouncing of the support of the MA's, and the RSI is looking good, but that's all I know right now, gotta read some more on the other indicators..
Hey Stockz, what do you think about eyii
SOYO - News -BDI-Laguna to Distribute SOYO LCD Monitors to Major Retailers Across the Nation
Business Wire - February 08, 2006 08:10
ONTARIO, Calif., Feb 08, 2006 (BUSINESS WIRE) -- SOYO(R) Group Inc. (OTCBB: SOYO), a global provider of computer, consumer electronics and broadband telecommunications products, today announced it has signed a distribution agreement with BDI-Laguna to make SOYO's Dymond brand LCD monitor line available to BDI-Laguna customers nationwide. BDI-Laguna's distribution channel is listed at the following Web site: http://www.esend.com/bdi/channels.htm.
Under this agreement, BDI-Laguna will offer SOYO LCD monitors to all customers in its expanding consumer electronics group, retail customers. BDI-Laguna has more than 20 years' experience in consumer electronics and computer product distribution, and operates warehouse facilities in Georgia, New Jersey and Nevada.
"BDI-Laguna's commitment to customer service and its expertise in distribution services and logistics are the perfect fit for our LCD market strategy," said Ming Chok, president and CEO of SOYO Group Inc. "By working with their team, we will be able to provide LCD computer monitor solutions to a wider customer base and ensure our product line is more immediately available."
"SOYO's Dymond brand LCD monitors are an outstanding addition to our portfolio," said Joel Blank, executive vice president, BDI-Laguna. "We believe that offering our customers top products like SOYO's LCD line, as well as outstanding service, gives them a significant advantage in the marketplace."
SOYO's Dymond LCD Monitor series is a family of flat-panel 17- and 19-inch LCD monitors, which incorporate TFT (Thin Film Transistor) display technology to deliver brilliant colors, fast display times and TV watching capabilities for consumers, corporate users and gamers. The models feature built-in stereo speakers and a front panel with auto adjustment, menu and volume controls and DVI support on the 19-inch models, which allows users to watch broadcast TV stations on the monitor. All models come with a two-year limited warranty.
BGAT - News; Bluegate Reports Preliminary Fourth Quarter Revenue Increase of 107% and Record Annual Revenues for 2005--Up 109%
Business Wire - February 08, 2006 07:30
HOUSTON, Feb 08, 2006 (BUSINESS WIRE) -- Reporting preliminary financial results for the fourth quarter and year end 2005, Bluegate Corp. (OTCBB:BGAT), the nation's premier provider of outsourced healthcare IT solutions, professional technology consulting services and Bluegate Medical Grade Networks(TM), announced that consolidated revenues for the fourth quarter ended December 31, 2005 were $777,000, an increase of 107% over $375,000 of total revenues for the comparable period in 2004. Bluegate's 2005 annual consolidated revenues were $2.3 million, an increase of 109% over revenues of $1.1 million for 2004.
During the third quarter of 2005, Bluegate acquired the business of Trilliant Corporation, an IT professional service consultant to hospitals and other large institutions. Strategically, Trilliant provides Bluegate an expanded health care IT solutions professional services capability to support Bluegate's growth in servicing its hospital, large medical practice and other centralized health care organizations (HCOs). The 2005 annual pro forma combined revenues of Trilliant and Bluegate would have been $3.0 million had the acquisition occurred on January 1, 2005.
"We are pleased to announce that we more than doubled our revenue this past year over 2004," stated Manfred Sternberg, Bluegate CEO. "With the continued expansion of our sales pipeline of healthcare IT solutions and Medical Grade Networks to hospitals, physicians, HCOs and other healthcare providers, and third party health care vendor application installation and management services, we reaffirm our forecast of revenues between $6 million and $7 million in 2006 and $11 million and $12 million in 2007. We continue to forecast positive cash flow by the end of the second quarter of 2006 as set forth in our December guidance."
"As public policy is accelerating the movement to electronic health records and the establishment of a National Healthcare Information Network (NHIN), there is growing recognition of the need for hospitals and medical practices to have secure medical grade networks and outsourced healthcare IT services," Sternberg stated. "These national health care initiatives simply cannot succeed without the involvement of the hospitals and their credentialed physicians, as well as independent physician practices. Bluegate is the leader in providing medical grade networks and outsourced healthcare IT services that enable secure communication between all points of the healthcare network--from hospitals to physician offices, clinics and all points in between. Our operational focus for 2006 and 2007 continues to be the build out of the Houston market, and strategic expansion to additional markets in Texas and other regions of the country where there is rapidly increasing demand for our networks and services."
About Bluegate
Bluegate Corp. is an industry leader of outsourced healthcare IT solutions, Medical Grade Networks(TM) and remote management services. It provides IT consulting through its professional services division and HIPAA-compliant, turnkey managed security services and interoperability solutions across its Medical Grade Networks(TM) to hospitals, physicians, other healthcare facilities, RHIOs, HCOs and third-party solution providers. Bluegate is publicly traded on the over the counter bulletin board under the ticker symbol BGAT. For information, visit www.bluegate.com or call 713-686-1100.
Safe Harbor
This press release may contain "forward-looking statements." All statements, other than statements of fact, included in this release and without limitation statements regarding potential future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements.
SOURCE: Bluegate Corp.
For Bluegate
Media:
Accentuate PR
Julie Shepherd, 815-479-1833
Julie@accentuatepr.com
or
Investors:
Diablo Consultants
Jeremy Roe, 925-932-1100
jeremygroe@diabloconsultants.com
Copyright Business Wire 2006
--------------------------------------------------------------------------------
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
PLRS - News -Pluristem Files Patent Application For Expanding Hematopoeitic Stem Cells (HSC) and Early Progenitor Cells from Cord Blood Non Selected Mono-Nuclear Cells (MNC)
Business Wire - February 08, 2006 07:30
HAIFA, Israel, Feb 08, 2006 (BUSINESS WIRE) -- Pluristem Life Systems, Inc. (OTC BB:PLRS: Company Identifies Simpler Approach for the Expansion of HSC Holding the Potential to Garner Significant Results and Allowing for a Substantially Larger Stem Cell Pool for Bone Marrow Transplantation
Pluristem Life Systems, Inc. (OTC BB:PLRS), a biotechnology company dedicated to the expansion of stem cells from umbilical cord blood to address a myriad of fatal illnesses, today announced that a patent application has been filed with the US Patent and Trademark Office for a new procedure for expanding Hematopoeitic Stem Cells (HSC) and early progenitor cells from Cord blood from non selected mono-nuclear cells (MNC) of the cord blood.
The methodologies used in current HSC expansion protocols apply a selection stage before the enrichment stage where the input cell population is defined by the expression of a cell membrane marker - CD34. This is a rare subpopulation of cells that are selected from large and mixed populations of mononuclear cells.
The selection process is associated with several drawbacks. First, it causes a substantial loss of source cells. Second and most importantly, the selected population of cells may not represent the earliest extractable population of HSC. Pluristem's expansion protocol is intended to overcome both hurdles by using cord blood from non-selected MNC to fuel the enrichment process.
This approach allows Pluristem to independently utilize two already patent protected processes: the selection of CD34 cells and use of proprietary manufactured cytokines.
Pluristem's advanced method for expanding target HSC population from cord blood is a two-fold approach. First, a state-of-the-art patented bioreactor mimicking the natural bone marrow environment is used. Second, MNC rather than CD34 selected cells are targeted as the starting source of HSC. The efficacy of the expansion process that utilizes non-selected MNC of the cord blood is superior to what is currently being achieved by using CD34 selected cells as the starting population of cells.
"This application represents the broadening of Pluristem's already strong and broad patent position in the area of stem cell expansion. Unique to Pluristem's approach in the arena is the 'human'-like bone marrow environment and the identification and use of CD34 marker stem cells - clearly providing Pluristem with a potentially highly favorable competitive stance in our industry," stated Zami Aberman, Pluristem's CEO.
For more information, visit the Company's website at: www.pluristem.com.
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements". Those statements include statements regarding the intent, belief or current expectations of Pluristem Life Systems, Inc., and members of our management as well as the assumptions on which such statements are based. Forward-looking statements in this release include statements regarding Pluristem independently utilizing two already patent protected processes to overcome drawbacks in current processes; that the efficacy of the expansion process that utilizes non-selected MNC of the cord blood is superior to what is currently being used by others; that Pluristem has a strong and broad patent position in the area of stem cell expansion; that we have a potentially highly favorable competitive stance in our industry. and that our technology offers opportunities for therapeutic products. Actual outcomes and our actual results could differ materially from those in such forward-looking statements, as we may find that our processes do not work as well in practice as in theory; we may encounter side effects or other adverse consequences of using our technology; our current patents may be attacked and defeated in patent proceedings; our patent filings may be rejected by the patent offices; other companies may discover and develop better or cheaper technologies that would render our processes obsolete; and we may not have sufficient funding to develop our technology. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.
SOURCE: Pluristem Life Systems, Inc.
for Pluristem Life Systems, Inc.
DeMonte Associates
Cynthia DeMonte, 718-706-5005
cdemonte@aol.com
Copyright Business Wire 2006
--------------------------------------------------------------------------------
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
NWWV - News NeWave's 'onlinesupplier.com' Surpasses Record 10 Million Hits In January
PR Newswire - February 08, 2006 07:33
GOLETA, Calif., Feb 08, 2006 /PRNewswire-FirstCall via COMTEX/ -- NeWave, Inc. (OTC Bulletin Board: NWWV -- News) today announced that wholly-owned subsidiary 'onlinesupplier.com' has for the first time ever registered over 10 million hits to its website in January, a monthly record for it.
NeWave CEO Michael Hill stated, "Registering a monthly record of 10 million hits to the onlinesupplier.com website in January is a testament to the increasing effectiveness of our online marketing campaigns. I believe these results maybe just a forecast of what we are capable of achieving this year."
About NeWave, Inc.
Through its websites 'onlinesupplier.com' and 'buydiscount.com', NeWave provides ecommerce solutions and thousands of high value products at significant savings to its online loyalty club customers and members.
To find out more about NeWave (OTC Bulletin Board: NWWV), visit our websites at www.newave-inc.com, www.onlinesupplier.com and www.buydiscount.com. The Company's public financial information and filings can be viewed at www.sec.gov.
Forward Looking Statements
And Good Mourning All,
LOUD- News- Loudeye Announces 2006 Operating Plan and Preliminary Fourth Quarter 2005 Financial Results
PR Newswire - February 08, 2006 07:05
Operating Plan Focuses on Key Markets & Customers and Reduced Cost Structure Fourth Quarter Revenue Exceeds Guidance Due to Approximate 92% Annual Growth in Digital Media Store Services
Feb 08, 2006 /PRNewswire-FirstCall via COMTEX/ -- Loudeye Corp. (Nasdaq: LOUD), a worldwide leader in business-to-business digital media solutions, today announced the implementation of a strategic operating plan focused on key markets and customers and streamlining its operations. This plan will enable Loudeye to eliminate redundancies and significantly reduce its cost structure, while minimizing impact on its largest revenue generating customers. This plan furthers the cost reduction initiatives implemented during the fourth quarter 2005, beginning with the exit of the Overpeer content protection services business. In addition, Loudeye announced record preliminary fourth quarter 2005 revenue and other preliminary financial results.
"We are implementing a plan which aligns our operations and investment behind the areas where we are seeing the most growth, while rationalizing our cost structure and accelerating margin improvement," said Mike Brochu, president and chief executive officer of Loudeye. "We are focusing on our largest markets and revenue generating customers, primarily in Europe, while retaining capabilities to support our strategic goals with mobile music services."
Key elements of Loudeye's 2006 operating plan are as follows:
Focus on Key Markets and Customers. Loudeye's operating plan will focus on the markets and customers which are generating the most economic value for the company. Approximately 80% of total fourth quarter revenue was generated by digital media store services, and substantially all digital media store services revenue was generated in Europe where Loudeye's services have a significant installed customer base. In addition, Loudeye will continue to operate its digital media content services located at its Seattle, Washington headquarters, including encoding and samples services. Loudeye has recently completed an upgrade to its content encoding services, increasing the automation of those services and improving their operating contribution.
Streamline Operations and Align Platforms. Loudeye will immediately align its product development, engineering, information technology and operational resources behind its largest markets and customers. Loudeye's digital media store service operations now will be centralized at its European headquarters in the United Kingdom. These steps will reduce redundant costs in the United States, while minimizing the impact on revenue generating customers in Europe. As part of this alignment, Loudeye has ceased development efforts on a custom digital music service for an unnamed North American retailer, the launch of which previously was delayed. Loudeye and this retailer have terminated their contract, and Loudeye will continue to pursue means to realize value from its investment in this service with other parties.
Reduce Cost Structure. Loudeye believes this plan will allow it to continue to grow revenue while reducing its cost structure significantly. In combination with its previously announced exit of the Overpeer content protection services business in December 2005, the actions taken or contemplated by today's announcement are expected to reduce Loudeye's cost structure by approximately $2.5 million per quarter, or approximately 30% compared to third quarter 2005 levels. Cost savings from these actions, which include personnel reductions and possible funded development, are expected to be realized by the end of the first quarter 2006.
Financing & Strategic Alternatives. In addition to a combination of increasing margins and reducing operating expenses, Loudeye continues to pursue measures to address its liquidity needs through securing additional investments or other strategic alternatives.
Preliminary Fourth Quarter 2005 Results
Fourth quarter 2005 revenue is estimated to be approximately $8.8 million, compared to approximately $6.5 million in the third quarter 2005 and $5.5 million in the fourth quarter 2004. These results exclude content protection services revenue which will be included in the loss from discontinued operations for financial reporting purposes. Digital media store services revenue represented approximately $7.1 million of total revenue, an approximate 48% increase from $4.8 million in the third quarter 2005 and an approximate 92% increase from $3.7 million in the fourth quarter 2004. Substantially all of the revenue growth in the fourth quarter 2005 was attributable to promotional services revenue from an internet service provider in Europe.
Gross profit for the fourth quarter 2005 is expected to be approximately $1.0 million. Excluding results from discontinued operations and other potential charges related to goodwill and other long-lived assets in the quarter, Loudeye expects a narrowed GAAP net loss compared to the third quarter 2005.
While Loudeye is encouraged by its revenue growth, it continues to experience significant losses and has limited cash reserves. Unrestricted and restricted cash, cash equivalents and marketable securities were approximately $10.8 million at December 31, 2005, compared to $16.6 million at September 30, 2005. Restricted cash as of December 31, 2005, was approximately $1.8 million compared to approximately $600,000 at September 30, 2005.
Loudeye intends to release its financial results for the fourth quarter and year-ended 2005 on Thursday, February 23, 2006. Management will host a conference call with investors and financial analysts to discuss these results and to provide further details about its 2006 operating plan at that time.
Preliminary unaudited fourth quarter results and details concerning the 2006 operating plan reflect management's expectations as of the date of this release and are based upon limited available information which is dynamic and subject to change. Results may be materially affected by many factors including those described in the Forward-Looking Statements section below.
About Loudeye Corp.
SONT- News; Sontra Medical Introduces Generation 1.75 SonoPrep(R) Skin Permeation Device>SONT
VWKM - News; Vision Works Media Group, Inc. Announces Ahead of Schedule - Goal $7,500,000 Monthly
Business Wire - February 07, 2006 09:13
ORLANDO, Fla., Feb 07, 2006 (BUSINESS WIRE) -- Vision Works Media Group, Inc. (Pink Sheets:VWKM) today announced that the company is three weeks ahead of schedule in the installation and setup required for satellite distribution in Atlanta.
Mr. Astrom said, "Our progress has put us ahead of schedule. The extra three weeks leading up to our April 1st national launch of New Screen Television can now be used for meeting with affiliates and future affiliates."
Astrom added, "Satellite distribution enables New Screen TV to reach each of the top 100 markets where we anticipate long-term revenues between $2,500,000-$7,500,000 monthly in subscription fees alone. With distribution via SES Americom's AMC-10 satellite, our goal of 50 million subscribing households is possible."
New Screen Television is an independent film television channel that broadcasts digitally nationwide utilizing the "HD Prime" platform on the SES Americom AMC-10 satellite, and terrestrially in Florida over-the-air utilizing WRCF-TV Channel 29 Orlando. New Screen TV joins the channels found on SES Americom's AMC-10 satellite, which (in unison with AMC-11) comprises "HD Prime - America's Cable Neighborhood." Other broadcasters utilizing the "HD Prime - America's Cable Neighborhood" platform include Discovery Communications, Scripps Networks, Viacom, E! Networks, A&E Television Networks, Hallmark Channel, Lifetime Entertainment, NBC, QVC and the Weather Channel.
GBIW - NEws; Genesis Bioventures Announces Worldwide Distribution Rights for Mad Cow Test
PR Newswire - February 07, 2006 09:05
NEW YORK, Feb 07, 2006 /PRNewswire-FirstCall via COMTEX/ -- Genesis Bioventures, Inc. (GBI) (OTCBB:GBIW) today announced that the Company has signed exclusive worldwide sales, marketing and distribution agreements with Prion Developmental Laboratories Inc. (PDL) to commercialize the recently patented Rapid Prion-Detection Assay tests developed by PDL.
The Rapid Prion-Detection Assay is designed to test for prion diseases, such as mad cow disease, directly at the point-of-kill rather than in a laboratory. The Assay is an easy-to-use rapid test strip that can be administered by trained individuals at slaughterhouses with visual results produced in less than 30 minutes.
"This exclusive sales, marketing and distribution agreement immediately satisfies the short term business objectives of both of our companies and concurrently allows us to focus our resources on continued science, technology and product development opportunities. Through this partnering agreement we will be able to advance the sales, marketing and distribution of our products faster and at lower cost to PDL. We expect the net benefit of this agreement will result in faster time to profitability for the company," said Robert B. Petersen, CEO of PDL.
Dr. Richard Rubenstein, PDL's Chief Scientific Officer, commenting on the agreement with GBI stated, "This agreement offers the opportunity to more rapidly proceed to PDL product sales and distribution and, at the same time, introducing its technology to the marketplace. Furthermore, PDL will now be able to concentrate its efforts on new product and technology developments."
"We are very pleased to announce this agreement with PDL," commented Greg McCartney, Chairman of GBI. "This agreement is the first of many corporate developments we are looking to accomplish this year. The global interest in Bovine Spongiform Encephalopathy (BSE, Mad Cow Disease) is at an all time high. PDL has an outstanding solution to this global problem that, working together, we can bring to market faster."
"As an investor in PDL, we want to help the company management and scientists to be able to focus their efforts in developing world-class, market leading diagnostic products based on their patented technology for human and animal health. Dr. Petersen and Dr. Rubenstein are highly respected scientists in the field. They have demonstrated outstanding capabilities to transform complex science and technology into easy to use commercial products," he continued.
"This agreement represents a strong step toward increasing the commercial opportunities available to both companies," stated Douglas C. Lane of Experigen Management, advisor to GBI. "GBI has a long term vision for PDL, including further investment in the company and continued interest in acquisition and other corporate partnering strategies. The exclusive agreement strengthens GBI's position in its current investment in PDL, which the company expects will produce higher shareholder value."
The worldwide agreement is the aggregate of two agreements between GBI and PDL, one for exclusive rights in Canada and one for exclusive rights in the United States, Japan, Europe and the rest of the world. The agreements specify that GBI has the right to appoint and sell Products to any Sublicensee or similar reseller and both agreements are for a five year period with automatic three year renewals.
Greg McCartney added, "These agreements place GBI and PDL in an extremely favorable position. Approximately 145 million cattle are slaughtered annually in the top 16 beef producing countries alone. It is also imperative for countries like Canada who export a majority of their beef and countries like Japan who import a majority of their beef to demonstrate the safety of their products. The cost and time effectiveness of the PDL test could allow for all animals to be tested, which would ensure food safety with very little added cost to the industry and the end consumer."
The US Patent and Trademark Office recently issued a Notice of Allowance for PDL's Rapid Prion-Detection Assay. PDL has already received USDA approval for its chronic wasting disease assay and is currently focusing on rapid diagnostic tests for mad cow disease and other animal TSEs.
About Prion Developmental Laboratories
PDL is a leading biotechnology company that researches, develops and produces advanced diagnostic and food safety monitoring tests for human and animal diseases caused by prions. Genesis Bioventures, Inc. has a significant investment in PDL.
About Genesis Bioventures, Inc.
Genesis Bioventures, Inc. is a biomedical development corporation focusing on the development and marketing of novel diagnostics and therapeutics in oncology and neurodegenerative diseases.
About Experigen Management
Experigen is a management company retained by Genesis Bioventures, Inc. to develop and advance GBI's investment portfolio, financing and operations.
Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
CONTACT:
GBI Investor Relations: (604) 542-0820, gbi@gnsbio.com, www.gnsbio.com
Experigen: (310) 443-4100, info@experigen.com, www.experigen.com
SOURCE Genesis Bioventures, Inc.
GBI Investor Relations: (604) 542-0820, gbi@gnsbio.com, www.gnsbio.com; Experigen:
(310) 443-4100, info@experigen.com, www.experigen.com
http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
--------------------------------------------------------------------------------
Copyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.